lily
Insilicon Intelligent and Eli Lilly reach up to $2.75 billion AI drug research and development cooperation agreement
Insilicon Intelligent announced a cooperation agreement with Eli Lilly and Company of up to about $2.75 billion to use AI engines to accelerate the discovery and development of new therapies. The agreement includes a $115 million down payment and subsequent milestone payments and sales tiered royalties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments